Page last updated: 2024-12-07

iodosulpride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iodosulpride is an atypical antipsychotic medication, mainly used to treat schizophrenia. It is a selective dopamine D2/D3 receptor antagonist with high affinity for D2 and D3 receptors, and low affinity for D1, D4, and serotonin receptors. Its effects are thought to be primarily mediated by its antagonism of dopamine D2 receptors in the mesolimbic pathway, which is implicated in the positive symptoms of schizophrenia, such as hallucinations and delusions. Iodosulpride is typically administered orally, and it is available in tablet form. Studies have shown that iodosulpride is effective in reducing the severity of positive symptoms in patients with schizophrenia. It has also been investigated for use in other conditions, such as depression, anxiety, and Tourette's syndrome. Iodosulpride is generally well-tolerated, but it can cause side effects, such as extrapyramidal symptoms, akathisia, and sedation. It is important to note that iodosulpride is not a cure for schizophrenia, and it should not be taken without a prescription from a healthcare professional. Its specific mechanism of action in relation to its clinical effects and the underlying biochemistry of the dopamine system is still under investigation, and it remains a significant area of research.'

iodosulpride: 125I labeled; selective ligand for brain dopamine receptors; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122245
MeSH IDM0131344

Synonyms (12)

Synonym
PDSP1_000525
PDSP2_000523
iodosulpride
n-[[1-(cyclopropylmethyl)pyrrolidin-2-yl]methyl]-5-ethylsulfonyl-4-iodo-2-methoxybenzamide
bdbm81796
nsc_122245
cas_122245
benzamide, n-((1-(cyclopropylmethyl)-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-4-iodo-2-methoxy-
n-((1-cyclopropylmethyl-2-pyrrolidinyl)methyl)-2-methoxy-4-iodo-5-ethylsulfonylbenzamide
100038-54-8
n-{[1-(cyclopropylmethyl)pyrrolidin-2-yl]methyl}-5-(ethanesulfonyl)-4-iodo-2-methoxybenzene-1-carboximidic acid
DTXSID80905185
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (17.95)18.7374
1990's21 (53.85)18.2507
2000's8 (20.51)29.6817
2010's3 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.86 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (97.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]